Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

Stock Information for Coherus Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Coherus Oncology Inc.

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025
Coherus Oncology to Participate in Upcoming Investor Conferences
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Coherus Oncology to Participate in Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.